title: Secondary myelodysplastic syndrome after treatment of prostate cancer with oral estramustine.
authors.forename: M
authors.initials: M
authors.lastname: Ando
authors.forename: K
authors.initials: K
authors.lastname: Tamayose
authors.forename: K
authors.initials: K
authors.lastname: Sugimoto
authors.forename: K
authors.initials: K
authors.lastname: Oshimi
mesh_terms: D000284:Administration, Oral; D000368:Aged; D004961:Estramustine / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000209:etiology; D008297:Male; D009190:Myelodysplastic Syndromes / Q000139:chemically induced*; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011878:Radiotherapy / Q000009:adverse effects
chemical_list: D004961:Estramustine